European Equity pre-Market Summary - 24th August 2026: potential Shell asset sale

• Shell (SHEL LN), -0.5%: Has drawn interest from potential bidders including ExxonMobil (XOM) and LyondellBasell (LYB) for its USD 8bln US chemicals assets sale, according to the FT citing sources. The figure, if correct, is seen as a steep discount.

• GSK (GSK LN): FDA has accepted priority review for Jemperli in dMMR/MSI-H locally advanced rectal cancer; PDUFA date is Feb 2027. Seperately, Japan approves Hibsago for chronic hepatitis B, marking its first global approval.

• Segro (SGRO LN): upgraded to Equal Weight from Underweight at Barclays
• Diploma (DPLM LN), +0.5%: upgraded to Overweight from Neutral at JPMorgan
• Sandvik (SAND SS), +1.5%: upgraded to Buy from Hold by SEB

% after the Co. name and ticker are the pre-market indication via Tradegate

Reported bidder interest from both a supermajor and a chemicals peer in Shell's US chemicals book fits a pattern that has run through the sector for some time: integrated oil companies pruning downstream and chemicals exposure, with strategic buyers and financial sponsors circling the divested assets. The detail doing the work here is the reported figure being characterised as a steep discount, since price tension between seller and bidders is the usual reason processes of this kind stall, restructure into partial sales, or get pulled; precedent in comparable divestment rounds is that initial press figures frequently differ from final agreed terms. The competitive tension between a deep-pocketed integrated rival and a chemicals operator is itself a tell, as the two buyer types value the same assets on different synergies and typically anchor different parts of the bid spectrum. The modest pre-market downtick suggests the discount framing, not the process itself, is what is being weighed. Follow-ons worth noting are any confirmation of a formal process, further named bidders, and management commentary on capital allocation and proceeds use, which is where these stories have historically clarified. The accompanying broker moves are routine rotation commentary and the drug filing follows the standard priority review timeline.